Develops cancer drugs designed with computer models of proteins.
New: first time
Duquesne bought Relay Therapeutics for the first time between April and June: 349,000 shares, worth about $7 million. That’s already less than $1 of every $100 they have in stocks.
Mar 31
None
Jun 30
349,000
The numbers
Shares they own
349,000
Value on Jun 30, 2026
$6,530,000
about $7 million
Share of their money
0.1%
less than $1 of every $100 · 74th of 85
Price per share on Jun 30
$18.71
Kind
Shares
Also owned by
No other fund we follow
More about Relay Therapeutics ›
The value uses the price on Jun 30, 2026. The fund may have paid a different price.